OBJECTIVE: Review the next generation of molecular targets in mCRPC.
EVIDENCE ACQUISITION: Medline databases were searched for >100 original articles published as of October 18, 2011, with the search terms metastatic castration-resistant prostate cancer, targeted therapy, biologic agents, and immunotherapy. Proceedings from the last 5 yr of conferences of the American Society of Clinical Oncology, American Urological Association, European Society of Medical Oncology, and the European Association of Urology were also searched. We included novel and promising drugs that have reached clinical trial evaluation.
EVIDENCE SYNTHESIS: The major findings were addressed in an evidence-based fashion. Prospective trials and important preclinical data were analyzed.
CONCLUSIONS: mCRPC is a disease with multiple molecular drivers. Molecular pathways being targeted in ongoing phase 3 trials are androgen signaling (MDV3100, TAK700), immunoregulatory pathways (ipilimumab, Prostvac-VF-TRICOM), Src (dasatinib), Met (cabozantinib), clusterin (custirsen), and angiogenesis (aflibercept, tasquinimod). The strides made in identifying multiple other novel molecular targets offer potential opportunities for further improving outcomes.
Written by:
Agarwal N, Sonpavde G, Sternberg CN. Are you the author?
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Reference: Eur Urol. 2011 Dec 22. Epub ahead of print.
doi: 10.1016/j.eururo.2011.12.028
PubMed Abstract
PMID: 22209376
UroToday.com Investigational Urology Section
